Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eiger Biopharmaceuticals (EIGR)
NASDAQ:EIGR
RESEARCH TOOLSreports
Eiger Biopharmaceuticals (EIGR) Stock Price & Analysis
592 Followers
EIGR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $43.35
Previous Close$1.99
Volume137.82K
Average Volume (3M)116.08K
Market Cap
$2.95M
Enterprise Value$18.75M
Total Cash (Recent Filing)$25.40M
Total Debt (Recent Filing)$41.20M
Price to Earnings (P/E)>-0.1
Beta1.99
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.80
Shares Outstanding1,480,797
10 Day Avg. Volume648,099
30 Day Avg. Volume116,075
Standard Deviation0.28
R-Squared0.12
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-1.75
Price to Sales (P/S)0.16
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eiger Biopharmaceuticals News
PremiumCompany Announcements
Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EIGR FAQ
What was Eiger Biopharmaceuticals’s price range in the past 12 months?
Eiger Biopharmaceuticals lowest stock price was $1.10 and its highest was $43.35 in the past 12 months.
What is Eiger Biopharmaceuticals’s market cap?
Currently, no data Available
When is Eiger Biopharmaceuticals’s upcoming earnings report date?
Eiger Biopharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 23 days.
How were Eiger Biopharmaceuticals’s earnings last quarter?
Eiger Biopharmaceuticals released its earnings results on Mar 14, 2024. The company reported -$9.094 earnings per share for the quarter, missing the consensus estimate of -$6.3 by -$2.794.
Is Eiger Biopharmaceuticals overvalued?
According to Wall Street analysts Eiger Biopharmaceuticals’s price is currently Overvalued.
Does Eiger Biopharmaceuticals pay dividends?
Eiger Biopharmaceuticals does not currently pay dividends.
What is Eiger Biopharmaceuticals’s EPS estimate?
Eiger Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiger Biopharmaceuticals have?
Eiger Biopharmaceuticals has 1,480,797 shares outstanding.
What happened to Eiger Biopharmaceuticals’s price movement after its last earnings report?
Eiger Biopharmaceuticals reported an EPS of -$9.094 in its last earnings report, missing expectations of -$6.3. Following the earnings report the stock price went down -11.167%.
Which hedge fund is a major shareholder of Eiger Biopharmaceuticals?
Among the largest hedge funds holding Eiger Biopharmaceuticals’s share is Carlson Capital LP. It holds Eiger Biopharmaceuticals’s shares valued at N/A.
---
Eiger Biopharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.1%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.07%
12-Months-Change
Fundamentals
Return on Equity
-367.00%
Trailing 12-Months
Asset Growth
-67.70%
Trailing 12-Months
Company Description
Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
---
EIGR Company Deck
---
EIGR Earnings Call
Q3 2022
0:00 / 0:00
---
EIGR Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering EIGR
1 Year
1 Year Success Rate
4/31 ratings generated profit
1 Year Average Return
-40.60%
reiterated a buy rating 5 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 12.90% of your transactions generating a profit, with an average return of -40.60% per trade.
---